References
- Caggiano V, Weiss RV, Rickert TS, . Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916–1924.
- Bodey GP, Buckley M, Sathe YS, . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328–340.
- Gafter-Gvili A, Fraser A, Paul M, . Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979–995.
- Bucaneve G, Micozzi A, Menichetti F, . Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–987.
- Ziglam HM, Gelly KJ, Olver WJ. A survey of the antibiotic treatment of febrile neutropenia in haematology units in the United Kingdom. Clin Lab Haematol 2005;27:374–378.
- Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004;33:735–739.
- Bucaneve G, Castagnola E, Viscoli C, . Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer Suppl 2007;5:5–12.
- Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003;37:1210–1215.
- Petitpretz P, Arvis P, Marel M, . Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185–195.
- Conde MB, Efron A, Loredo C, . Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183–1189.
- Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005;353:1052–1054.
- Wright DH, Brown GH, Peterson ML, . Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46:669–683.
- Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998;27:33–39.
- De Pauw B, Walsh TJ, Donnelly JP, . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821.
- von Baum H, Sigge A, Bommer M, . Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006;58:891–894.
- Cooper MA, Andrews JM, Wise R. In-vitro activity of tosufloxacin, a new quinolone antibacterial agent. J Antimicrob Chemother 1992;29:639–647.
- Niki Y. Pharmacokinetics and safety assessment of tosufloxacin tosilate. J Infect Chemother 2002;8:1–18.
- Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl. 2):S144–S157.
- Meersseman W, Lagrou K, Maertens J, . Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007;45:205–216.
- Schwartz RS, Mackintosh FR, Schrier SL, . Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984;53:411–419.
- Maraki S, Lionakis S, Ntaoukakis M, . Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans. Med Mycol 2011;49:419–423.
- Samonis G, Kofteridis DP, Maraki S, . Levofloxacin and moxifloxacin increase human gut colonization by Candida species. Antimicrob Agents Chemother 2005;49:5189.